Cargando…
Enhancing chimeric antigen receptor T‐cell immunotherapy against cancer using a nanoemulsion‐based vaccine targeting cross‐presenting dendritic cells
OBJECTIVES: Adoptive transfer of chimeric antigen receptor (CAR)‐modified T cells is a form of cancer immunotherapy that has achieved remarkable efficacy in patients with some haematological cancers. However, challenges remain in CAR T‐cell treatment of solid tumours because of tumour‐mediated immun...
Autores principales: | Chan, Jack D, von Scheidt, Bianca, Zeng, Bijun, Oliver, Amanda J, Davey, Ashleigh S, Ali, Aesha I, Thomas, Ranjeny, Trapani, Joseph A, Darcy, Phillip K, Kershaw, Michael H, Dolcetti, Riccardo, Slaney, Clare Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374388/ https://www.ncbi.nlm.nih.gov/pubmed/32704371 http://dx.doi.org/10.1002/cti2.1157 |
Ejemplares similares
-
Chimeric antigen receptor T cell therapies for thoracic cancers—challenges and opportunities
por: Chan, Jack D., et al.
Publicado: (2020) -
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
por: Tantalo, Daniela GM, et al.
Publicado: (2021) -
Tissue‐specific tumor microenvironments influence responses to immunotherapies
por: Oliver, Amanda J, et al.
Publicado: (2019) -
Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses
por: Oliver, Amanda J., et al.
Publicado: (2020) -
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
por: Oliver, Amanda J., et al.
Publicado: (2018)